Protagonist updates pipeline: rusfertide Ph3 enrollment Q1 2024; JNJ-2113 Ph3 psoriasis data Nov 2024

Protagonist Therapeutics, Inc

Rusfertide Phase 3 VERIFY study enrollment completion expected Q1 2024; primary endpoint similar to Phase 2.
Phase 2 REVIVE showed 69.2% responder rate vs 18.5% placebo (p=0.0003); durable Hct control to 2.5 years.
Rusfertide improved fatigue (p=0.0074) and concentration (p=0.0018) scores; ferritin normalized over 2.5 years.
JNJ-2113 Phase 3 ICONIC-LEAD psoriasis primary completion ~Nov 2024; Phase 2b ANTHEM UC completion ~Nov 2024.
Anticipated rusfertide NDA filing Q4 2026; JNJ-2113 NDA filing expected 2025/2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.